Details
In 2020, Illumina will be releasing a new version of its TruSight™ Oncology 500 assay, designed for use with circulating tumor DNA in liquid biopsy testing. In this webinar, taken from a live presentation given at AMP 2019, Dr. Biswajit Das of the Frederick National Laboratory (FNL)/MoCHA and Dr. Stephanie Hastings of Q2 Solutions discuss their validation studies. They share their observations regarding specificity and sensitivity of TruSight™ Oncology 500 ctDNA in detecting low level of variants in circulating tumor DNA, and its ability to assess multiple variant classes in a single assay. They also discuss their plans to incorporate TruSight™ Oncology 500 ctDNA into future clinical trials and research studies.
Analytical Validation of Illumina’s TSO500™ ctDNA pre-released version assay
Stepanie B. Hastings, PhD
Staff Scientist II in Assay Development
Translational Genomics at Q2 Solutions
TSO500™ ctDNA pre-released version: Pan-Cancer Liquid Biopsy Assay Platform for NCI Clinical Studies
Biswajit Das, PhD
Molecular Characterization Laboratory
Frederick National Laboratory of Cancer Research
Fill Out Form to Access Webinar
- Date & Time
- Nov 6, 2019
- 8:00 AM
- Location
- North America
- Affiliation
- Q2 and NCI
- Presenter
- Stephanie Hastings and Biswajit Das
- Topic
- Oncology, Cancer research